An experimental daily pill designed to treat early Alzheimer’s disease slowed cognitive decline by 31 percent among patients not taking other memory medications, biotechnology company AriBio announced Monday at the 2026 Clinical Trials on Alzheimer’s Disease conference.
The Phase 3 trial, known as POLARIS-AD, evaluated 1,535 participants with early Alzheimer’s over 52 weeks. While the drug, called AR1001, did not demonstrate a statistically significant benefit across the full group of participants, it met one of its primary endpoints by showing a significant slowing of decline in a subgroup of 604 patients who were taking no other Alzheimer’s treatments, BioSpace and The Telegraph reported.
A Novel Biological Mechanism
AR1001 is an oral medication that blocks an enzyme called PDE5, utilizing the same biological pathway as the erectile dysfunction drug Viagra. By inhibiting PDE5, the once-daily pill relaxes blood vessels to increase blood flow to the brain, aiming to protect brain cells, according to reports. Analysis of spinal fluid from trial participants showed elevated levels of cyclic guanosine monophosphate, confirming that the drug acted on its intended biological target within the central nervous system.
Dr. Sharon Sha, global principal investigator for the trial and chief of the Memory Disorders Division at Stanford University, said the results among patients not taking other Alzheimer’s drugs were encouraging, noting the drug’s safety profile while emphasizing that further research remains necessary.
Dr. Richard Oakley, associate director for research and innovation at the Alzheimer’s Society, told The Telegraph that the trial offered promising news for future care. “These topline results are an exciting sign that we could have a totally new treatment for early Alzheimer’s disease that tackles its causes, not just its symptoms,” Oakley said.
Subgroup Results and Safety Profile
Researchers measured clinical deterioration using an 18-point scale that evaluates memory, judgment, and daily functioning. Over the one-year study, participants in the 604-patient subgroup who received AR1001 experienced a 0.44-point smaller decline than those given a placebo pill. In contrast, the overall study population showed a non-significant treatment difference of 0.11 points, representing a 7 percent slowing of decline.
If eventually approved, AR1001 would offer a simple oral alternative to existing disease-modifying treatments like Biogen and Eisai’s Leqembi and Eli Lilly’s Kisunla, both of which require infusions or injections. In Phase 3 trials, Leqembi slowed decline by 27 percent over 18 months, while Kisunla slowed decline by 29 percent over 76 weeks, BioSpace reported.
AriBio reported that AR1001 was generally well tolerated, with serious adverse events occurring in similar proportions between the treatment and placebo groups. Diarrhea, dizziness, and falls were the most common side effects, with diarrhea reported in 7.7 percent of patients on AR1001 compared to 4.4 percent on placebo. About 5 percent of patients discontinued the medication due to adverse events, compared to less than 2 percent of placebo recipients. Researchers noted no evidence of brain swelling, a side effect associated with anti-amyloid treatments.
Next Steps for Drug Approval
AriBio CEO Jai-Jun Choung said the 31 percent slowing of decline in the monotherapy group supports the hypothesis behind developing a practical, long-term oral option for Alzheimer’s patients and caregivers.
The company plans to present its findings to the U.S. Food and Drug Administration to explore regulatory pathways for approval. Meanwhile, most participants who completed the 52-week trial have enrolled in an extension study where all participants receive AR1001, with final results expected next year.



